Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
Here is the second part of Dr. Socinski's summary from our ASCO Highlights in Lung Cancer program, covering an important presentation by Dr. Rogerio Lilenbaum that directly compared a platinum-based doublet of carboplatin/Alimta (pemetrexed) to Alimta as a single agent in patients with a performance status of 2. Dr. Lilenbaum has done a lot of work focusing on the elderly and marginal performance status patients, and this work has largely illustrated that they are not one in the same: elderly patients with a good performance status have consistently done better with more aggressive doublet therapy. So what about patients of any age with a more marginal performance status?
Below you'll find the audio and video versions of Dr. Socinski's coverage of the trial, along with the transcript and figures from his presentation.
Dr. Socinski ASCO 2012 LC Highlights PS2 Single Agent vs Doublet Trial Audio Podcast
Dr. Socinski ASCO 2012 LC Highlights PS2 Single Agent vs Doublet Trial Transcript
Dr. Socinski ASCO 2012 LC Highlights PS2 Single Agent vs Doublet Trial Figs
We'll continue posting additional parts of this program every few days.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…